The Politics of Evidence Use in Health Policy Making in Germany-the Case of Regulating Hospital Minimum Volumes. [PDF]
, 2017 This article examines the role of scientific evidence in informing health policy decisions in Germany, using minimum volumes policy as a case study. It argues that scientific evidence was used strategically at various stages of the policy process both by
Ettelt, S
core +3 more sources
The Democratic Biopolitics of PrEP [PDF]
, 2019 PrEP (Pre-Exposure Prophylaxis) is a relatively new drug-based HIV prevention technique and an important means to lower the HIV risk of gay men who are especially vulnerable to HIV.
Adam D Galinsky +84 more
core +5 more sources
Der Gemeinsame Bundesausschuss als Motor für die Initiierung klinischer Studien? Eine kritische Analyse [PDF]
Gesundheits- und Sozialpolitik, 2020 Die Rolle des Gemeinsamen Bundesausschusses bei der Innovationsbewertung hat sich in den letzten Jahren grundlegend gewandelt. Der G-BA hat zunehmend auch die Aufgabe übernommen, selbst Wissen zu generieren und Studien zu initiieren. Aufbauend auf den Erfahrungen aus einem prominenten Beispiel, der PREFEREStudie, diskutiert der Beitrag, welche ...
Antje Gottberg +2 more
openaire +1 more source
Indikationsspezifische Kosten-Nutzen-Bewertung auf Grundlage eines sozialen Gesundheitsindexes [PDF]
, 2010 Dieser Beitrag entwickelt einen Vorschlag zur indikationsspezifischen Kosten-Nutzen-Bewertung. Zentrales Konzept ist ein sozialer Gesundheitsindex, der die Leistung des Gesundheitswesens misst. Er berücksichtigt nicht nur das Niveau der Gesundheit in der
Kifmann, Mathias
core +1 more source
Questioning Patient Subgroups for Benefit Assessment: Challenging the German Gemeinsamer Bundesausschuss Approach [PDF]
Value in Health, 2014 Questioning Patient Subgroups for Benefit Assessment: Challenging the German Gemeinsamer Bundesausschuss Approach Jorg Ruof, MD, MPH, MBA*, Charalabos-Markos Dintsios, PhD, MPH, Friedrich Wilhelm Schwartz, MD Roche Pharma AG, Grenzach-Wyhlen, Germany; Hannover Medical School, Hannover, Germany; German Association of Researchbased Pharmaceutical ...
Ruof, Jörg +2 more
openaire +2 more sources
Analyse des vorläufigen Berichtsplans des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen für eine Kosten-Nutzen-Bewertung zu Clopidogrel bei der peripheren arteriellen Verschlusskrankheit und beim akuten Koronarsyndrom [PDF]
, 2010 --
Aidelsburger, Pamela, Wasem, Jürgen
core +3 more sources
Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward [PDF]
, 2016 List of regulatory documents organized per country and list of publications.
Alexandra Nolting +4 more
core +7 more sources
The German health care Innovation Fund – An incentive for innovations to promote the integration of health care [PDF]
, 2021 Purpose – Many health systems face challenges such as rising costs and lacking quality, both of which can be addressed by improving the integration of different health care sectors and professions.
Auschra, Carolin +5 more
core +1 more source
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe [PDF]
, 2016 Background The aim of this study was to review and compare types of reimbursement recommendations for orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement status of these drugs in the corresponding ...
Kawalec, Paweł +2 more
core +2 more sources
A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence [PDF]
, 2017 Background: Opioid dependence is a chronic condition with substantial health, economic and social costs. The study objective was to conduct a systematic review of published health-economic models of opioid agonist therapy for non-prescription opioid ...
Chetty, Mersha +4 more
core +8 more sources